<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Not</title>
	<atom:link href="http://www.tapanray.in/tag/not/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>What Have And Haven’t Changed In Pharma’s New Normal?</title>
		<link>http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-have-and-havent-changed-in-pharmas-new-normal</link>
		<comments>http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/#comments</comments>
		<pubDate>Sun, 26 Sep 2021 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Aduhelm]]></category>
		<category><![CDATA[analytics]]></category>
		<category><![CDATA[augmenting]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[changed]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[customers]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hits]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[misses]]></category>
		<category><![CDATA[modeling]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Oxymoron]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[repurposed]]></category>
		<category><![CDATA[sensitivity]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[trends]]></category>
		<category><![CDATA[triggered]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10588</guid>
		<description><![CDATA[While navigating through the challenge of disruptive changes, several pharma marketers are now focusing more on creating, connecting, and leveraging all market and customer related data, across the organization. Astute ones are using state-of-the-art tools, platforms, and techniques to gain &#8230; <a href="http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Vaccines Development: Is it Just a Business Based on Fear?</title>
		<link>http://www.tapanray.in/vaccines-development-is-it-just-a-business-based-on-fear/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=vaccines-development-is-it-just-a-business-based-on-fear</link>
		<comments>http://www.tapanray.in/vaccines-development-is-it-just-a-business-based-on-fear/#comments</comments>
		<pubDate>Mon, 26 Aug 2013 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[Buchwald]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[diphtheria]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[enough]]></category>
		<category><![CDATA[Expenses]]></category>
		<category><![CDATA[fear]]></category>
		<category><![CDATA[First]]></category>
		<category><![CDATA[Gates]]></category>
		<category><![CDATA[GAVI]]></category>
		<category><![CDATA[Gerhard]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[JV]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[malaria]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[MSD]]></category>
		<category><![CDATA[NCD]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Partnership]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pox]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TB]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[Tuberculosis]]></category>
		<category><![CDATA[vaccination]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3486</guid>
		<description><![CDATA[‘Vaccination – A Business based on fear’, is the title of a book written by Dr. Gerhard Buchwald M.D, a German medical doctor and a vaccination critic. This book talks about: “The damage and the deaths caused by vaccination are written &#8230; <a href="http://www.tapanray.in/vaccines-development-is-it-just-a-business-based-on-fear/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/vaccines-development-is-it-just-a-business-based-on-fear/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Innovation Absolutely Critical: But NOT Shorn from Ethics, Propriety, Compliance and Values</title>
		<link>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values</link>
		<comments>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/#comments</comments>
		<pubDate>Mon, 20 May 2013 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[apathy]]></category>
		<category><![CDATA[bribing]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[buzzword]]></category>
		<category><![CDATA[Caesar]]></category>
		<category><![CDATA[Caesar's]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[concealment]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[corrupt]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[denigrating]]></category>
		<category><![CDATA[developed world]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[fall]]></category>
		<category><![CDATA[FCPA]]></category>
		<category><![CDATA[fines]]></category>
		<category><![CDATA[fixing]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[fraud]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[globalized]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[grease]]></category>
		<category><![CDATA[guy]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[isolation]]></category>
		<category><![CDATA[leaders]]></category>
		<category><![CDATA[lower]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[middle]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[off-label]]></category>
		<category><![CDATA[overcharging]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[propriety]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[religious]]></category>
		<category><![CDATA[scrutiny]]></category>
		<category><![CDATA[spiritual]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[suspicion]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[Talk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[Values]]></category>
		<category><![CDATA[walk]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[wife]]></category>
		<category><![CDATA[X factors]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2481</guid>
		<description><![CDATA[Significant value added innovation is the bedrock of progress of the pharmaceutical industry and is essential for the patients. This is a hard fact. However, this current buzzword – ‘innovation’ can in no way be shorn from soft business necessities &#8230; <a href="http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Old is Always Not Gold&#8217;: The Saga of Uncertainty on the New Drug Policy Continues</title>
		<link>http://www.tapanray.in/old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues</link>
		<comments>http://www.tapanray.in/old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues/#comments</comments>
		<pubDate>Mon, 19 Nov 2012 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Always]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Continues]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[gold]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[uncertainty]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1066</guid>
		<description><![CDATA[Along with the initiation of globalization process of India in 1991, many significant reform oriented steps are being taken by the Government for the pharmaceutical industry as its growth booster. In tandem with gradual reduction in the span of price &#8230; <a href="http://www.tapanray.in/old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Tracking MDG 6 in India – not a mean achievement to combat the dreaded disease</title>
		<link>http://www.tapanray.in/tracking-mdg-6-in-india-not-a-mean-achievement-to-combat-the-dreaded-disease/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=tracking-mdg-6-in-india-not-a-mean-achievement-to-combat-the-dreaded-disease</link>
		<comments>http://www.tapanray.in/tracking-mdg-6-in-india-not-a-mean-achievement-to-combat-the-dreaded-disease/#comments</comments>
		<pubDate>Thu, 16 Jun 2011 23:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[6]]></category>
		<category><![CDATA[achievement]]></category>
		<category><![CDATA[combat]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[dreaded]]></category>
		<category><![CDATA[goals]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MDG]]></category>
		<category><![CDATA[mean]]></category>
		<category><![CDATA[millennium]]></category>
		<category><![CDATA[MMR]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Tracking]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=241</guid>
		<description><![CDATA[At the turn of the new millennium, in 2000, 189 nations of the world under the banner of United Nations Development Program took a pledge to free people from extreme poverty and multiple deprivations. This global pledge for humanity on &#8230; <a href="http://www.tapanray.in/tracking-mdg-6-in-india-not-a-mean-achievement-to-combat-the-dreaded-disease/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/tracking-mdg-6-in-india-not-a-mean-achievement-to-combat-the-dreaded-disease/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The top two reasons for not seeking medical treatment, across the population, are not poor ‘Access to Healthcare’ in India</title>
		<link>http://www.tapanray.in/the-top-two-reasons-for-not-seeking-medical-treatment-across-the-population-are-not-poor-access-to-healthcare-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-top-two-reasons-for-not-seeking-medical-treatment-across-the-population-are-not-poor-access-to-healthcare-in-india</link>
		<comments>http://www.tapanray.in/the-top-two-reasons-for-not-seeking-medical-treatment-across-the-population-are-not-poor-access-to-healthcare-in-india/#comments</comments>
		<pubDate>Mon, 07 Feb 2011 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Across]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[poor]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reasons]]></category>
		<category><![CDATA[rich]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[seeking]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[urban]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=305</guid>
		<description><![CDATA[“About 1.8 million children under age of 5 die in India every year; 68,000 mothers die due to maternal causes, and 52 million children in the country are stunted”. “With 70% people living in more than 600,000 villages across rural &#8230; <a href="http://www.tapanray.in/the-top-two-reasons-for-not-seeking-medical-treatment-across-the-population-are-not-poor-access-to-healthcare-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-top-two-reasons-for-not-seeking-medical-treatment-across-the-population-are-not-poor-access-to-healthcare-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Have the successive ‘Drug Policies’ of India delivered? If not, why not?</title>
		<link>http://www.tapanray.in/have-the-successive-drug-policies-of-india-delivered-if-not-why-not/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=have-the-successive-drug-policies-of-india-delivered-if-not-why-not</link>
		<comments>http://www.tapanray.in/have-the-successive-drug-policies-of-india-delivered-if-not-why-not/#comments</comments>
		<pubDate>Mon, 17 Jan 2011 01:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[cheap]]></category>
		<category><![CDATA[delivered]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Have]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[If]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policies]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[successive]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[why]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=314</guid>
		<description><![CDATA[January 11, 2011 edition of ‘The Lancet’ in its article titled, “Financing health care for all: challenges and opportunities&#8221; commented as follows: “India&#8217;s health financing system is a cause of and an exacerbating factor in the challenges of health inequity, &#8230; <a href="http://www.tapanray.in/have-the-successive-drug-policies-of-india-delivered-if-not-why-not/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/have-the-successive-drug-policies-of-india-delivered-if-not-why-not/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Limiting FDI in Pharma is a protectionist cry: Does not benefit the common man.</title>
		<link>http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man</link>
		<comments>http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/#comments</comments>
		<pubDate>Sat, 08 Jan 2011 16:30:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[100%]]></category>
		<category><![CDATA[49%]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[automatic]]></category>
		<category><![CDATA[benefit]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[common]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[cry]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Does]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[Limiting]]></category>
		<category><![CDATA[man. foreign]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[protectionist]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[route]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=317</guid>
		<description><![CDATA[“Protectionism is harmful” very aptly commented by Mr. Pranab Mukherjee, the Finance Minister of India, just the other day. This was in context of “recent US moves to hike visa fees and clamp down on outsourcing”. While almost at the &#8230; <a href="http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Creating an IPR friendly robust ‘Echo-System’ and &#8216;Improving Access to Affordable Medicines&#8217; are not either/or situation in India</title>
		<link>http://www.tapanray.in/creating-an-ipr-friendly-robust-echo-system-and-improving-access-to-affordable-medicines-are-not-eitheror-situation-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=creating-an-ipr-friendly-robust-echo-system-and-improving-access-to-affordable-medicines-are-not-eitheror-situation-in-india</link>
		<comments>http://www.tapanray.in/creating-an-ipr-friendly-robust-echo-system-and-improving-access-to-affordable-medicines-are-not-eitheror-situation-in-india/#comments</comments>
		<pubDate>Mon, 13 Sep 2010 01:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[Eco-System]]></category>
		<category><![CDATA[either/or]]></category>
		<category><![CDATA[friendly]]></category>
		<category><![CDATA[Improving]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[situation]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=375</guid>
		<description><![CDATA[Last year, though the growth of the Global Pharmaceutical Industry with a turnover of US$ 752 billion significantly slowed down to just 6.7% due to various contributing factors, the Indian Pharmaceutical Industry continued to maintain a robust of growth of &#8230; <a href="http://www.tapanray.in/creating-an-ipr-friendly-robust-echo-system-and-improving-access-to-affordable-medicines-are-not-eitheror-situation-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/creating-an-ipr-friendly-robust-echo-system-and-improving-access-to-affordable-medicines-are-not-eitheror-situation-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>85% of the patented new drugs have therapeutic equivalents…they do not increase the cost of treatment for the common man: Points…Counterpoints</title>
		<link>http://www.tapanray.in/85-of-the-patented-new-drugs-have-therapeutic-equivalentsthey-do-not-increase-the-cost-of-treatment-for-the-common-man-pointscounterpoints/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=85-of-the-patented-new-drugs-have-therapeutic-equivalentsthey-do-not-increase-the-cost-of-treatment-for-the-common-man-pointscounterpoints</link>
		<comments>http://www.tapanray.in/85-of-the-patented-new-drugs-have-therapeutic-equivalentsthey-do-not-increase-the-cost-of-treatment-for-the-common-man-pointscounterpoints/#comments</comments>
		<pubDate>Mon, 21 Jun 2010 01:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[85%]]></category>
		<category><![CDATA[common]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Counterpoints]]></category>
		<category><![CDATA[do]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[equivalent]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Have]]></category>
		<category><![CDATA[increase]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[man]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Points]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[they]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=412</guid>
		<description><![CDATA[Affordability of patented drugs has become a major controversial and at the same time a very sensitive issue in the healthcare space of India, just as in many other parts of the world. The government, the NGOs and other stakeholders, &#8230; <a href="http://www.tapanray.in/85-of-the-patented-new-drugs-have-therapeutic-equivalentsthey-do-not-increase-the-cost-of-treatment-for-the-common-man-pointscounterpoints/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/85-of-the-patented-new-drugs-have-therapeutic-equivalentsthey-do-not-increase-the-cost-of-treatment-for-the-common-man-pointscounterpoints/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
